Galderma Group AG announced the launch of its hyaluronic acid injectable filler, Restylane VOLYME in China. The company is also introducing its complementary Shape Up Holistic Individualized Treatment in the country, which addresses aging concerns caused by loss of structural support in the mid-face. The availability of these targeted solutions for the mid-face region is demonstrative of Galderma?s commitment to meeting patient and injector needs in China.

In the past decade, the growth of China?s aesthetics medicine market has outpaced the global market; with relatively low market penetration, there remains significant potential for future growth. Developed using Galderma?s proprietary OBT gel technology, Restylane VOLYME is indicated for the correction of mid-face volume deficit and/or mid-face contour deficiency through injections into the subcutaneous to supraperiosteal layers of the skin. Hyaluronic acid fillers are often patients?

first choice for mid-face augmentation and have been shown to deliver high patient satisfaction and long-lasting effects. In China, hyaluronic acid fillers are among the top 10 most-sold aesthetics products. Developed with a global community of injectors, the Shape Up HIT is the latest of Galderma?s HITs to be introduced in China, designed to create a common language to facilitate a two-way dialogue between patient and practitioner to align on patient priorities and keep satisfaction at the forefront.

HIT is an individualized treatment approach which enables injectors to leverage their expertise with the renowned Galderma Restylane portfolio to optimize aesthetic outcomes while prioritizing patient satisfaction. The Balanced Profile HIT was Galderma?s first HIT to be introduced in China in 2023, providing a framework for practitioners to conduct a full objective facial assessment for the patient and help bring balance to their profile. HIT naturally springboards from Galderma?s AART (Assessment, Anatomy, Range, Treatment) methodology for a new generation of individualized aesthetics.

Restylane is the largest and most diverse range of individually engineered hyaluronic acid fillers on the market, approved in more than 80 countries and regions, and with over 65 million treatments administered worldwide.